Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3377716 | Journal of Microbiology, Immunology and Infection | 2016 | 5 Pages |
Abstract
Allergic bronchopulmonary aspergillosis (ABPA) is a severe type of asthma. Some cases are resistant to treatment, even with regular use of antiasthmatic drugs and antifungal agents. The diagnosis of ABPA was made in a 40-year-old patient with ABPA according to the Rosenberg-Patterson criteria. Symptoms were not controlled despite regular use of antiasthmatic drugs, daily systemic steroids, and antifungal agents. Omalizumab, administered in an attempt to stabilize these uncontrolled symptoms, was effective with no adverse events. Our experience suggests omalizumab is a potential candidate drug for controlling steroid-dependent ABPA.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Tetsuya Homma, Masatsugu Kurokawa, Satoshi Matsukura, Munehiro Yamaguchi, Mitsuru Adachi,